The Management Committee of the Cardiovascular Health Across the Lifespan Program (CHAL) is headed by the program leader, associate leader and manager. Membership also includes the Chief of Cardiology of the McGill University Health Centre (MUHC), three internal representatives from the Centre for Translational Biology (CTB) , the Centre for Innovative Medicine (CIM) and the Centre for Outcomes Research and Evaluation (CORE) , and one representative from another research program. The Management Committee seeks to expand the cardiovascular aspect of the CHAL program to include interdisciplinary experts performing cutting-edge translational biomedical research.
Dr. Ariane Marelli, Program Leader
Dr. Stella S. Daskalopoupou, Associate Program Leader
Dr. Louis Doré-Savard, Program Manager
Dr. Nadia Giannetti, Chief of Cardiology, MUHC
Dr. Louise Pilote, Population health representative (CORE)
Dr. Jacques Genest, Basic research representative (CTB)
Dr. Mathias Friedrich, Clinical research representative (CIM)
Dr. Keith Murai, External representative, Leader of the Brain Repair and Integrative Neuroscience (BRaIN) Program
|Ariane Marell, MD is Professor of Medicine at McGill University and is the Associate Director for Research and Academic Affairs for Cardiology at the McGill University Health Centre. She is an associate member of the Department of Epidemiology, Biostatistics and Occupational Health. Her research interests involve the impact of the changing epidemiology of congenital heart disease on health services delivery, quality and policy. Her research tools have included large administrative databases and electronic health records. She created and manages a population-based congenital heart disease database that covers over 100,000 patients with congenital heart disease from birth to old age in Quebec, from 1983 to 2010. Along with Dr. Jack Lewin, CEO of the American College of Cardiology, she was a first recipient of the 2011 Heart Heroes Award from the Adult Congenital Heart Association in recognition of "visionary leadership in epidemiology, quality of care and health IT for congenital heart disease patients." Her research is supported by the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada and the Fonds de recherche du Québec−Santé (FRQS). She is a clinical research scholar of the FRQS. |
Stella S. Daskalopoulou, MD, PhD is a tenured Associate Professor of Medicine at McGill University. She established and directs the Vascular Health Unit at the McGill University Health Centre, where she conducts research projects on vascular structure and function, including the identification of novel pathways of atherosclerotic plaque instability, image analysis of atherosclerosis plaque composition, and arteriosclerosis, with special interest in arterial stiffness and hemodynamics in subjects with cardiovascular risk factors, such as hypertension, smoking, diabetes, dyslipidemia, and pre-eclampsia. Dr. Daskalopoulou's research has led to over 100 peer-reviewed publications. She is a member of the central review committee of the Canadian Hypertension Education Program (CHEP), the Executive Committee of the Société des Sciences Vasculaires du Québec, and the North America Artery Society. Dr. Daskalopoulou has received several personal awards, including the Hypertension Canada New Investigator Award, the Young Researcher Award of Excellence from the Heart and Stroke Foundation of Quebec, the Canadian Foundation for Women's Health Research, the Bourse Fonds de recherche du Québec−Santé (FRQS) ─La Société Québécoise d'Hypertension Artérielle Jacques-de-Champlain, and the Canadian Society of Internal Medicine New Investigator award. Dr. Daskalopoulou holds several research grants from the Canadian Institutes of Health Research, FRQS, Heart and Stroke Foundation of Canada and Canada Foundation for Innovation Leaders Opportunity Fund, amongst others. She is a clinical research scholar of the FRQS.
Louis Doré-Savard, PhD holds a doctorate in physiology from the Université de Sherbrooke, where he investigated chronic pain in several models, including bone metastasis. He then pursued training in tumour biology and medical imaging at The Johns Hopkins School of Medicine as a postdoctoral fellow. In 2016 he joined the Research Institute of the McGill University Health Centre to complete a second postdoctoral fellowship in breast cancer and bone metastasis treatment, developing an expertise in animal models of cancer, preclinical micro-imaging and translational research. Dr. Doré‑Savard thus brings 11 years of experience and leadership in biomedical research to the Cardiovascular Health Across the Lifespan Program.